Engitix develops tissue- and disease-specific human extracellular matrix scaffolds, vital tools in the acceleration and improvement of the drug discovery process.
The RSA Group was appointed to find a Chief Scientific Officer for Engitix. It was essential that the individual had substantial experience in discovery research in a variety of therapeutic areas. They also needed to be competent working at the interface between pre-clinical and clinical work. At the company’s stage of development, the appointee also needed to have experience working with early-stage biotechs and global pharma companies as well as having credibility at Board level.
How our approach made a difference:
We ran a global search, with a particular focus on Europe. The careful due diligence of our consultants and excellent communication with the client resulted in a shortlist of four strong candidates. The person appointed had over 20 years’ experience across biologics and small molecule drug discovery, having held several senior leadership roles. He has since made a great contribution and helped build the Company’s scientific team.